The prevalence of diabetes in the general population is high and rising. The diabetic population is at increased risk of mortality and severity of COVID-19 infection. This observation is valid for the various countries affected by the pandemic. Mechanisms remain to be understood, but one of the hypotheses put forward is the alteration in the inflammatory response.
This is the reason why it is important to understand the pathophysiological mechanisms that make the diabetic disease a severity risk factor for the COVID-19 infection.
To compare the value of ENDOCAN, an indicator of blood vessel inflammation, in diabetic and non-diabetic patients hospitalized for COVID-19. The aim is to assess the importance of the inflammatory context and the increased risk of morbidity and mortality in the diabetic population infected with COVID-19.